Alpha 2.0
Login Register
» Authors » Prashant Tembhare

Prashant Tembhare

Explore the profile of Prashant Tembhare including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 1449
Followers 0
Related Specialties
Hematology
Oncology
Pathology
Top 10 Co-Authors
Nikhil Patkar
Sumeet Gujral
P G Subramanian
Navin Khattry
Bhausaheb Bagal
Manju Sengar
Gaurav Narula
Anant Gokarn
Hasmukh Jain
Gaurav Chatterjee
Published In
Indian J Pathol Microbiol
Cytometry B Clin Cytom
Leuk Lymphoma
Indian J Hematol Blood Transfus
Blood Adv
Affiliations
Soon will be listed here.
Recent Articles
1.
Fifth edition WHO classification: myeloid neoplasms
Chen X, Patkar N, Tembhare P, Papagudi S, Yeung C, Kanagal Shamanna R, et al.
J Clin Pathol . 2025 Feb; PMID: 39947884
The fifth edition of the WHO classification of haematolymphoid tumours (WHO-HEM5) introduces significant advancements in the understanding and diagnosis of myeloid neoplasms, emphasising molecular and genetic insights. This review highlights...
2.
A comparison of mobilization regimens used in Hodgkin lymphoma and factors that influence peripheral blood stem cell mobilization
Gokarn A, Reddy L, Hiregoudar S, Poojary M, Parab S, Punatar S, et al.
Cytotherapy . 2025 Feb; PMID: 39903142
Background: Various chemotherapy regimens have been used for chemo-mobilization of stem cells prior to autologous stem cell transplant in patients with Hodgkin lymphoma, and there is no clear standard of...
3.
Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort
Roy Moulik N, Keerthivasagam S, Chatterjee G, Agiwale J, Rane P, Dhamne C, et al.
Am J Hematol . 2024 Nov; 100(2):210-217. PMID: 39568222
Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%-3% of all childhood leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their...
4.
Real World Outcomes with Treatment Free Remission in Chronic Myeloid Leukemia-Experience from a Tertiary Care Cancer Centre
Sarma R, Kashyap L, Srikanth A, Mondal T, Kashyap Y, Nandhana R, et al.
Indian J Hematol Blood Transfus . 2024 Oct; 40(4):564-572. PMID: 39469157
Chronic myeloid leukaemia (CML) is caused by balanced translocation t(9::22)(q34;q11) resulting in formation of pathogenic BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. Ongoing treatment...
5.
Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort
Roy Moulik N, Keerthivasagam S, Pandey A, Agiwale J, Hegde K, Chatterjee G, et al.
Br J Haematol . 2023 Dec; 204(4):1249-1261. PMID: 38098201
Tyrosine kinase inhibitors (TKIs) have drastically improved the outcomes of pCML (paediatric CML) but data on long-term off-target toxicities of TKIs in children are scarce. In this single-centre, retrospective cum...
6.
KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1
Srinivasan S, Dhamne C, Patkar N, Chatterjee G, Roy Moulik N, Chichra A, et al.
Pediatr Blood Cancer . 2023 Nov; 71(2):e30791. PMID: 38014874
Background: Pediatric core binding factor acute myeloid leukemia (CBF-AML), although considered a favorable risk subtype, exhibits variable outcomes primarily driven by additional genetic abnormalities, such as KIT mutations. Procedure: In...
7.
Low levels of CD26 on certain cellular subtypes of donor harvest is associated with better clinical outcomes post allogeneic stem cell transplantation through regulation of NF-κB pathway and pro-inflammatory cytokines
Kandekar S, Punatar S, Khattry N, Gokarn A, Jindal N, Mirgh S, et al.
Int Immunopharmacol . 2023 Oct; 125(Pt A):111054. PMID: 37890379
Background: We had previously reported significant association of immunoectoenzyme CD26 expression on donor harvest with acute Graft-versus-Host-Disease (aGVHD) in allogeneic stem cell transplantation (ASCT) patients. The current study was aimed...
8.
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Gaur T, Poddutoori R, Khare L, Bagal B, Rashmi S, Patkar N, et al.
J Exp Clin Cancer Res . 2023 Jul; 42(1):186. PMID: 37507802
Introduction: The emergence of resistance to the highly successful BCL2-directed therapy is a major unmet need in acute myeloid leukemia (AML), an aggressive malignancy with poor survival rates. Towards identifying...
9.
Treating relapsed B cell-precursor ALL in children with a setting-adapted mitoxantrone-based intensive chemotherapy protocol (TMH rALL-18 PROTOCOL) - experience from Tata Memorial Hospital, India
Roy Moulik N, Keerthivasagam S, Velagala S, Gollamudi V, Agiwale J, Dhamne C, et al.
Ann Hematol . 2023 Jul; 102(10):2835-2844. PMID: 37479890
The outlook of relapsed ALL in low- and middle-income countries (LMICs) is dismal due to high treatment-related toxicities and inadequate resources. We report our experience of using a locally adapted...
10.
Treatment of Pediatric Acute Promyelocytic Leukemia with Retinoic Acid and Arsenic Trioxide along with Chemotherapy
Srinivasan S, Dhamne C, Roy Moulik N, Chichra A, Tembhare P, Patkar N, et al.
Indian J Pediatr . 2023 Jun; 91(6):564-570. PMID: 37380920
Objectives: Outcomes of childhood acute promyelocytic leukemia (APL) have exceeded 90% in the era of differentiating agents. In resource-limited settings, early mortality secondary to coagulopathy remains a significant challenge. Differentiation...